Studies using first-generation PARP inhibitors such as 3-AB 5 have shown that these inhibitors enhance the effects of DNA-methylating agents such as temozolomide (TMZ) 17 and dacarbazine (DTIC) 19 (see Figure 8), used in treating brain tumors and melanomas [71,72]. This evidence concerns the gene PARP1 and melanoma.